

Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature

Joshua A. Hill,^{1,2,3*} Manoj P. Menon,^{1,2,3} Shireesha Dhanireddy,¹ Mark M. Wurfel,¹ Margaret Green,¹ Rupali Jain,^{1,4} Jeannie D. Chan,^{1,4} Joanne Huang,^{1,4} Danika Bethune,⁵ Cameron Turtle,^{1,3} Christine Johnston,^{1,2} Hu Xie,³ Wendy M. Leisenring,³ H. Nina Kim,¹ Guang-Shing Cheng^{1,3}

¹Department of Medicine, University of Washington, Seattle, WA; ²Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA; ³Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; ⁴University of Washington School of Pharmacy; ⁵University of Washington School of Medicine

*Corresponding author.

Running Head: Tocilizumab for COVID-19

Key Words: SARS-CoV-2; COVID-19; tocilizumab; immunomodulatory

Abstract: 200

Manuscript: 3,370

Figures: 3

Tables: 4

References: 49

Supplementary materials: Yes

Corresponding Author:

Joshua A. Hill, MD

Assistant Professor, Fred Hutchinson Cancer Research Center and University of Washington

1100 Fairview Ave N, Mail Stop E-400

Seattle, WA 98109

Tele: 206-667-6504

e-mail: jahill3@fredhutch.org

1 **ABSTRACT**

2 **Background**

3 Coronavirus disease 2019 (COVID-19) due to infection with SARS-CoV-2 causes substantial morbidity.
4 Tocilizumab, an interleukin-6 receptor antagonist, might improve outcomes by mitigating inflammation.

5
6 **Methods**

7 We conducted a retrospective study of patients admitted to the University of Washington Hospital system with
8 COVID-19 and requiring supplemental oxygen. Outcomes included clinical improvement, defined as a two-
9 point reduction in severity on a 6-point ordinal scale or discharge, and mortality within 28 days. We used Cox
L0 proportional-hazards models with propensity score inverse probability weighting to compare outcomes in
L1 patients who did and did not receive tocilizumab.

L2
L3 **Results**

L4 We evaluated 43 patients who received tocilizumab and 45 who did not. Patients receiving tocilizumab were
L5 younger with fewer comorbidities but higher baseline oxygen requirements. Tocilizumab treatment was
L6 associated with reduced CRP, fibrinogen, and temperature, but there were no meaningful differences in Cox
L7 models of time to clinical improvement (adjusted hazard ratio [aHR], 0.92; 95% CI, 0.38-2.22) or mortality
L8 (aHR, 0.57; 95% CI, 0.21-1.52). A numerically higher proportion of tocilizumab-treated patients had
L9 subsequent infections, transaminitis, and cytopenias.

L10
L11
L12
L13
L14
L15
L16
L17
L18
L19
L20
L21 **Conclusions**

L22 Tocilizumab did not improve outcomes in hospitalized patients with COVID-19. However, this study was not
L23 powered to detect small differences, and there remains the possibility for a survival benefit.

L24
L25 **Key Words:** SARS-CoV-2, COVID-19, coronavirus, tocilizumab, immunomodulatory
L26

1 INTRODUCTION

2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel human pathogen
3 responsible for the largest global challenge to public health and humanity in over a century. Due to the high
4 pathogenicity of this novel virus and a lack of pre-existing immunity, millions of individuals have been infected
5 worldwide.(1) Among those infected, approximately 14% develop progressive pulmonary disease (coronavirus
6 disease 2019 [COVID-19]) that results in critical illness in 5% of individuals.(2) Given high mortality rates in
7 older patients and those with underlying comorbidities, there is an urgent need to identify effective therapies.

8 A profound inflammatory response to viral infection appears to be responsible for severe disease
9 manifestations in patients with COVID-19. High serum levels of C-reactive protein (CRP), ferritin, and
10 interleukin 6 (IL-6) are observed in patients requiring oxygen support and who progress to respiratory failure,
11 cardiovascular collapse, and death and are consistent with a hyperinflammatory cytokine storm.(3–5) These
12 laboratory and clinical findings are similar to the cytokine release syndrome (CRS) that may develop in cancer
13 patients receiving chimeric antigen receptor immunotherapy (CAR-T cell therapy),(6) which has overlapping
14 characteristics with macrophage activation syndrome (MAS).(7) Cytokine storm, and the resulting
15 immunopathology, has also been identified as a cause of morbidity associated with related coronaviruses
16 (SARS-CoV-1, Middle East Respiratory Syndrome-CoV) and other respiratory viruses.(8–11)

17 Treatment with corticosteroids, which suppress immune responses nonspecifically, has not been shown
18 to improve outcomes with other severe respiratory viral infections or acute respiratory distress syndrome
19 (ARDS) in the general population.(12) However, recent clinical trial data demonstrate a mortality benefit of low
20 dose dexamethasone for COVID-19 in hospitalized patients requiring supplemental oxygen or mechanical
21 ventilation,(13) supporting the notion that hyperinflammation contributes to disease pathogenesis among
22 patients with severe COVID-19 disease. The increasing use of cytokine-specific immunomodulatory agents in
23 other conditions has led to intense interest in the use of these agents for COVID-19. The rationale for use of
24 immunomodulatory therapies in patients with COVID-19 is extrapolated from the experience in CAR-T cell
25 therapy recipients, in whom IL-6 receptor blockade with tocilizumab (Actemra) can rapidly attenuate symptoms
26 of CRS.(6) In this context, tocilizumab does not appear to independently increase risk for infection,(14, 15)
27 although infectious complications are reported with chronic use in rheumatoid arthritis,(16) particularly with
28 concurrent immunosuppressants. Cytokine blockade for hyperinflammatory syndromes is supported by

1 additional lines of evidence, including the finding that treatment with recombinant IL-1 receptor antagonist,
2 anakinra (Kineret), may improve outcomes in patients with MAS-like features in the setting of sepsis.(17)

3 Since the beginning of the pandemic, multiple observational reports have suggested that tocilizumab
4 improves respiratory, radiological, and inflammatory parameters associated with COVID-19, although there are
5 conflicting results with regard to clinical outcomes.(18–24) Observational studies using either another anti-IL-6
6 receptor antagonist, sarilumab (Kevzara), or anakinra have shown similar findings.(25–28) However, there are
7 no published prospective randomized controlled trials that have proven efficacy for these anti-cytokine
8 therapies for COVID-19. Furthermore, the safety of immunomodulatory therapy in the context of an active
9 infection is not well understood. IL-6 is an essential aspect of immune control for many viral infections, but
L0 overproduction of IL-6 may be detrimental to viral clearance and survival.(10, 29) Thus, there is a critical need
L1 to understand the efficacy and safety of tocilizumab in patients with COVID-19. The aims of this observational
L2 study were to comprehensively describe the clinical course and outcomes of hospitalized patients with COVID-
L3 19 who were treated with tocilizumab and compare to patients from the same time period who were not treated
L4 with tocilizumab, describe adverse effects, and to evaluate the kinetics of inflammatory markers after
L5 tocilizumab therapy. In addition, we summarize the existing peer-reviewed literature regarding tocilizumab and
L6 COVID-19.

1 METHODS

2 Patients

3 We used the University of Washington (UW) Enterprise Data Warehouse to retrospectively identify all
4 individuals admitted to three UW Hospitals across the Seattle metropolitan region between March 19th (the first
5 date of tocilizumab administration) and April 24th, 2020 with SARS-CoV-2 detection in a respiratory sample.
6 Patients were excluded if they did not require supplemental oxygen, died or were placed on comfort measures
7 within two days of admission (in the no tocilizumab cohort only), or received an alternative anti-cytokine
8 therapy as part of clinical care or a trial. This study was approved by the UW Institutional Review Board.
9

10 Treatment, supportive care, and monitoring

11 Hospital system-wide guidelines pertaining to the use of COVID-19-specific therapies were formulated
12 using the limited available data by an interdisciplinary committee. During the study period, this guidance
13 recommended use of open label hydroxychloroquine or investigational remdesivir in patients requiring
14 supplemental oxygen and not participating on a corresponding clinical trial. The guidelines recommended
15 consideration of a single dose of tocilizumab 400 mg intravenously in patients who had persistent fever and
16 either impending or current respiratory failure, hemodynamic instability requiring vasopressor or inotropic
17 support, or a serum IL-6 level >5 times the upper limit of normal (range, 0-6 pg/mL). Tocilizumab was
18 contraindicated in patients with sepsis due to another infection, transaminases >5 times the upper limit of
19 normal, severe neutropenia (neutrophil count <500 cells/mm³), or severe thrombocytopenia (platelet count
20 <50,000 cells/mm³). Corticosteroids and other antivirals were not recommended at that time. Patients received
21 prophylactic heparin or enoxaparin for prevention of deep vein thrombosis at the discretion of the treating
22 physician. Laboratory testing for inflammatory markers (IL-6, C-reactive protein [CRP], ferritin, fibrinogen,
23 lactate dehydrogenase [LDH], and D-dimer) were recommended at the time of admission, every three days,
24 with clinical deterioration, and prior to discharge.
25

26 Outcomes

27 The primary outcome was sustained (≥3 days) clinical improvement within 28 days after baseline. For
28 patients treated with tocilizumab, baseline was considered to be at the time of tocilizumab administration. For

1 patients not treated with tocilizumab, baseline was considered to be 2 days after hospitalization to align with
2 the median number of days between hospitalization and tocilizumab administration in the tocilizumab cohort
3 (median, 1.8; IQR, 0.8-3.8). Clinical improvement was defined as a two-point reduction in patients' baseline
4 status on a six-point ordinal scale (modified from the WHO guidelines), or live discharge from the hospital,
5 whichever came first. The ordinal scale consisted of 1, discharged; 2, hospitalized but not requiring oxygen; 3,
6 hospitalized and requiring any supplemental oxygen; 4, hospitalized and requiring high-flow oxygen devices or
7 non-invasive ventilation; 5, hospitalized and requiring invasive ventilation; and 6, death.(30) We also analyzed
8 mortality within 28 days.

9 We described additional clinical outcomes of sepsis (defined as requiring hemodynamic support with
10 vasopressors, with resolution at the time of vasopressor discontinuation), thrombotic events, bacteremia, and
11 microbiologically confirmed pneumonia with another pathogen prompting antimicrobial therapy. We also
12 described the kinetics of inflammatory laboratory markers, temperature, and heart rate.

14 **Data collection and statistical considerations**

15 We abstracted data from medical records and electronic databases from the time of index admission for
16 COVID-19 through 28 days after baseline as defined above. We described the proportion of patients with
17 clinical improvement (as defined above) overall and stratified by baseline severity categories. We estimated
18 the cumulative incidence of clinical improvement treating death as a competing risk. To mitigate differences in
19 baseline characteristics between those who did and did not receive tocilizumab, we modeled the probability of
20 treatment using baseline characteristics and calculated weights for inverse probability of treatment weighting
21 (IPTW) analyses to weight the distribution of covariates to that of the overall population. Weights were
22 standardized using the marginal probability of treatment and truncated at the 98th percentile (values >4) to
23 reduce variability.(31) We carried out multivariable Cox proportional-hazards modelling to evaluate the
24 association of receipt of tocilizumab with 1) clinical improvement and with 2) mortality using IPTW and
25 unweighted models. Robust variances were utilized in IPTW models to account for inclusion of the weights.(31)
26 We also computed the restricted mean survival time (RMST) difference for time to clinical improvement and
27 adjusted these models using IPTW. This analysis provides an intuitively appealing estimate of the difference in

1 the mean number of days to clinical improvement between treatment groups.(32) Variables with a p-value <0.2
2 in univariable analyses were candidates for inclusion in the multivariable model; tocilizumab was included in all
3 models, irrespective of univariate results. Variables were retained in the multivariable model if their inclusion
4 modified the tocilizumab hazard ratio by more than 10% or if they were significantly associated with the
5 outcome. In Cox models and RMST calculations for time to clinical improvement, patients who died before day
6 28 without clinical improvement were assigned a censored follow-up time at day 28, essentially giving them the
7 worst possible “infinite” outcome. Additionally, we described the kinetics of changes in vital signs and
8 laboratory results, as well as the occurrence of other clinical events including thrombosis and infections. SAS
9 version 9.4 (SAS Institute, Cary, NC) and RStudio were used for analyses.

L0

L1 **Literature review**

L2 A literature search was conducted on July 10, 2020 via PubMed using the following search terms:
L3 (tocilizumab OR IL-6 OR interleukin-6) AND (COVID OR coronavirus OR SARS-CoV-2). Abstracts were
L4 reviewed to identify studies of individuals with confirmed SARS-CoV-2 infection who were treated with
L5 tocilizumab. Only studies with a comparator arm (i.e. no receipt of tocilizumab) were included.

1 RESULTS

2 Patient and treatment characteristics

3 Between March 19th, 2020 and April 24th, 2020, 44 patients were treated with tocilizumab. During this
4 time period, an additional 120 patients were hospitalized with COVID-19 but did not receive tocilizumab. After
5 excluding patients who did not require supplemental oxygen, who died or were placed on comfort measures
6 within two days of admission, or who were enrolled in a placebo-controlled trial of IL-6 receptor blockade with
7 sarilumab, there were 43 patients in the tocilizumab cohort and 45 patients in the non-tocilizumab cohort
8 (**Figure S1**). Demographic and clinical characteristics of each cohort are shown in **Table 1** and stratified by
9 baseline severity in **Table S1**. Compared to patients who did not receive tocilizumab, patients treated with
10 tocilizumab were more likely to be younger, of white Hispanic race and ethnicity, without chronic lung disease,
11 full code status, and receiving invasive ventilation (42% versus 20%) or high-flow oxygen (47% versus 22%).
12 The invasive ventilation groups were similar overall. Most patients in both groups were treated with
13 hydroxychloroquine, a minority (30%) were treated with remdesivir or placebo as part of a double-blind
14 randomized clinical trial,(33) and 1 patient received open-label compassionate use remdesivir. No patients
15 received corticosteroids for the treatment of COVID-19. The majority of patients received a single 400 mg
16 intravenous dose of tocilizumab (median, 4.7mg/kg; **Table S2**); 3 patients received a second dose within 24
17 hours after the first.

19 Clinical improvement

20 All patients were followed for up to 28 days after the baseline date or the time of death, whichever
21 occurred first. In the tocilizumab cohort, 26 (60%) patients were discharged from the hospital, 9 (21%) died,
22 and 8 (19%) remained hospitalized. In the no tocilizumab cohort, 27 (60%) patients were discharged from the
23 hospital, 15 (33%) died, and 3 (7%) remained hospitalized. Among patients not requiring invasive ventilation at
24 baseline and who did not have a 'do not intubate' code status, 5 of 15 (33%) and 0 of 3 (0%) patients
25 progressed to invasive ventilation in the tocilizumab and no tocilizumab cohorts, respectively. The proportion of
26 patients in each baseline severity category who met the clinical improvement endpoint are depicted in **Figure**
27 **1**, and longitudinal patient outcomes are depicted in **Figure S2**.

1 There were no differences in the cumulative incidence of clinical improvement among patients who did
2 and did not receive tocilizumab overall or stratified by baseline severity categories (**Figure S3**). Among
3 patients who improved, the median times to clinical improvement in the tocilizumab versus no tocilizumab
4 cohorts, respectively, were 8 versus 6 days in the low-flow subgroup, 11 versus 9 days in the high-flow
5 subgroup, and 16 versus 13 days in the invasive ventilation subgroup (**Table S3**).

6 To mitigate differences in baseline characteristics between tocilizumab treated and non-tocilizumab
7 treated patients, we generated standardized IPTW weights from propensity scores (**Figure S4 A-B**). After
8 truncating the two highest values, the IPT weighted population showed improvement in the balance of baseline
9 characteristics between patients who did and did not receive tocilizumab (**Figures S4 C-D; Table S4**). In an
L0 adjusted Cox model using the truncated IPTW weights, receipt of tocilizumab was not associated with a
L1 difference in clinical improvement (adjusted hazard ratio [aHR], 0.92; 95% CI, 0.38-2.22; **Table 2**). Exploratory
L2 models within baseline oxygen categories had similar findings but were limited by small numbers within
L3 stratum (data not shown). There was also no evidence for a significant difference in the time to clinical
L4 improvement in an IPTW adjusted RMST analysis, which demonstrated that patients receiving tocilizumab
L5 improved an average of 1.08 days faster (RMST -1.08, 95% CI, -5.59 to 8.63 days, $p=0.61$). A cumulative
L6 incidence plot of time to clinical improvement using the IPT weighted population is shown in **Figure 2**.

L7

L8 **Mortality**

L9 An adjusted Cox model using the truncated IPTW weights demonstrated a lower observed risk of
L0 mortality within 28 days among patients treated with tocilizumab compared to those not treated with
L1 tocilizumab (aHR, 0.57; 95% CI, 0.21-1.52; **Table 2**). However, this estimate was highly variable and was not
L2 significant; as such, we cannot infer any difference in mortality between the treatment groups. A Kaplan-Meier
L3 survival curve using the IPT weighted population is shown in **Figure S5**.

L4

L5 **Other clinical outcomes**

L6 Sepsis within 1 day of tocilizumab or baseline date in the non-tocilizumab group occurred in 9 and 7
L7 patients, respectively. Of the 9 tocilizumab patients, 7 survived (78%) with a median time to sepsis resolution

1 of 3.7 days (IQR, 1.5-7.3); 2 patients died with ongoing sepsis 5 and 14 days after tocilizumab. Of the 7 non-
2 tocilizumab treated patients, 3 survived (43%) with a median time to resolution of 13 days (IQR, 13-15); 4
3 patients died with ongoing sepsis at 1, 5, 12, and 14 days after baseline.

4 We also explored the potential benefit of tocilizumab for reducing thrombotic events. A numerically
5 higher proportion of patients developed thrombotic events in the tocilizumab cohort (n=4, 9%) than in the non-
6 tocilizumab cohort (n=2, 4%; **Table S5**). In addition, we evaluated potential adverse events associated with
7 tocilizumab treatment. We found that a numerically higher proportion of patients in the tocilizumab cohort had
8 bacteremia, secondary pneumonia, transaminitis, neutropenia, or thrombocytopenia within 14 days after
9 baseline in the tocilizumab cohort (**Table 3**).

L1 **Effect of tocilizumab on clinical and laboratory markers of inflammation**

L2 Laboratory values were similar at baseline for the tocilizumab and no tocilizumab cohorts (**Figure 3**).
L3 Among most patients who received tocilizumab, there was a rapid and sustained decrease in temperature
L4 (**Figure S6**), CRP, and fibrinogen. There was an initial increase followed by a decrease in IL-6 levels after
L5 administration of tocilizumab as expected given the mechanism of action of blocking the IL-6 receptor. Levels
L6 of LDH declined over days, and there was minimal change in ferritin and D-dimer levels. Heart rates rapidly
L7 declined but changes were not sustained over time (**Figure S6**). In contrast, levels of all biomarkers were
L8 relatively stable in the no tocilizumab cohort.

1 DISCUSSION

2 Morbidity and mortality remain unacceptably high in patients with COVID-19. The clinical utility of
3 directed immunomodulatory agents to preempt or reverse the cytokine-driven inflammation responsible for
4 much of this morbidity has biological plausibility,(34) but there are limited data to guide treatment strategies.
5 Although tocilizumab resulted in normalization of multiple inflammatory biomarkers, we did not find clear
6 evidence that tocilizumab improved clinical outcomes, although we were not powered to detect small effects,
7 and we cannot rule out a survival benefit. There were numerically more infections, transaminitis, and
8 cytopenias in individuals treated with tocilizumab.

9 Published observational studies have provided mixed results in terms of the associated benefits of
10 tocilizumab treatment in hospitalized patients with COVID-19 (**Table 4**). Our literature review of studies with a
11 comparator arm illustrate substantial heterogeneity in patients, their treatments, definitions of outcomes, and
12 analytic approaches. Most studies, including ours, are limited by residual indication bias among those receiving
13 tocilizumab. Rapidly evolving improvements in supportive care strategies may also confound findings of better
14 outcomes with tocilizumab over time. In our study of patients with heterogeneous disease severity, we did not
15 demonstrate an apparent clinical benefit of treatment with tocilizumab. Patients receiving tocilizumab in our
16 study were younger and sicker on presentation, and thus more likely to receive aggressive care early in the
17 pandemic. Our study was not confounded by the use of corticosteroids, unlike most other observational
18 studies. This is relevant given emerging data of the benefit of corticosteroids in patients with severe
19 disease.(35). The possibility still remains that there is a clinical scenario in which tocilizumab is beneficial, but
20 this will be best demonstrated through randomized clinical trials.

21 We also tested the novel hypothesis that thrombotic events may be reduced in tocilizumab-treated
22 patients. This could be an additional benefit of tocilizumab based on the high frequency of venous thrombosis
23 in patients with COVID-19.(36) It is biologically plausible that tocilizumab could reduce risk for thrombosis
24 given studies demonstrating reduced plasma levels of the procoagulant Factor XIII (fibrin-stabilizing factor), d-
25 dimer levels, and other inflammatory markers in patients receiving tocilizumab.(37–40) Although we
26 demonstrate a clear anti-inflammatory effect with rapid and marked reductions in serum levels of CRP and
27 fibrinogen, a higher proportion of patients in the tocilizumab group in our study had thrombotic events, which
28 may be due to the higher baseline disease severity in the tocilizumab group. It is possible that thromboembolic

1 events were underdiagnosed overall during the study period.(36, 41) The low number of events and
2 differences in characteristics between the patient subgroups limit conclusions, but the role of tocilizumab for
3 reducing thrombosis may warrant additional study in randomized trials.

4 Due to the potential for increased infection risk with chronic use of tocilizumab in patients with
5 rheumatoid arthritis,(16) we evaluated secondary infections. Although a numerically higher proportion of
6 patients in the tocilizumab cohort had a microbiologically confirmed secondary infection, this was likely related
7 to more patients requiring invasive ventilation in the tocilizumab group, resulting in more diagnoses of
8 ventilator-associated pneumonias. Some studies report higher rates of infections in patients receiving
9 tocilizumab (**Table 4**), although this may not compromise the potential benefits of tocilizumab.(24) We also
10 report numerically higher rates of transaminitis and cytopenias in patients receiving tocilizumab. These
11 comparisons were all limited by a small number of events and may reflect differences in the distribution of
12 disease severity between the two groups. Our findings do not suggest obvious safety concerns related to
13 tocilizumab use for COVID-19, consistent with the majority of studies.

14 Finally, we evaluated the effect of tocilizumab on clinical and laboratory markers of inflammation.
15 Similar to other studies of tocilizumab in patients with cytokine release syndrome and COVID-19,(18, 42) we
16 demonstrated a rapid and sustained effect on lowering body temperature, CRP, and fibrinogen. This may play
17 a role in the higher rates of resolution of sepsis physiology that we describe in our cohort and as reported in
18 another study.(43) The anti-inflammatory effects also suggest that the ~4 mg/kg dose used in our patients was
19 sufficiently bioactive. Whether the kinetics of inflammatory biomarkers correlate with response to tocilizumab
20 warrants further study.

21 The primary limitations of our study include those inherent to a retrospective, non-randomized design.
22 Higher baseline severity status in the tocilizumab cohort, as well as other differences in patient characteristics,
23 resulted in imbalances in the patient cohorts. To control for some of these differences, we compared outcomes
24 within baseline severity categories and performed IPTW adjusted analyses. For most comparisons, we were
25 limited to detecting relatively large differences. Strengths of this study include the relatively large cohort of
26 patients requiring noninvasive and invasive oxygenation, along with careful adjustment for differences in
27 patient characteristics and other confounders. We performed an RMST analysis for time to clinical
28 improvement that is novel to studies of tocilizumab for COVID-19 and provide a tangible measure of treatment

1 effect.(32) We performed comprehensive chart review and data abstraction to describe and analyze a variety
2 of clinical and laboratory outcomes to evaluate the potential benefits and side effects of tocilizumab therapy,
3 including novel comparisons of thrombotic events and resolution of sepsis physiology. Our data were not
4 confounded by steroids, and most patients did not receive remdesivir.

5 In conclusion, there was no clear evidence of improved clinical outcomes among hospitalized patients
6 with COVID-19 who received one dose of 400 mg of tocilizumab without concurrent steroids or effective
7 antivirals. Tocilizumab was associated with a robust reduction in inflammatory biomarkers; further study in
8 patients with sepsis physiology may be warranted. Randomized controlled trials using tocilizumab in the
9 context of concurrent effective antiviral and steroid therapy will be particularly important to guide evolving
L0 treatment strategies.

Acknowledgements: We acknowledge the University of Washington Division of Allergy and Infectious Diseases Research Collaboratory, including Ayushi Gupta and Kristine Lan, for help with data abstraction and analysis. We acknowledge Rina Romano and Joyce Maalouf for help with chart review, as well as Aimee Forquera and Linda Lei for patient care coordination. We appreciate the assistance of Ashley Sherrid for the literature review.

Funding: None

Author contributions: J.A.H., M.M., H.N.K., and G.S.C designed the study and interpreted the data. J.A.H., M.M., S.D., M.G., R.J., J.C., J.H., and G.S.C. contributed to data collection. J.A.H., H.N.K., H.X. and W.M.L. analyzed the data and created the figures. J.A.H. drafted the manuscript. All authors contributed to the writing and revision of the manuscript and approved the final version.

Competing interests: None

REFERENCES:

1. World Health Organization. 2020. Coronavirus disease (COVID-19) Situation Report – 133. June 1, 2020.
2. Wu Z, McGoogan JM. 2020. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. *JAMA - J Am Med Assoc*. American Medical Association.
3. Wang Z, Yang B, Li Q, Wen L, Zhang R. 2020. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China | *Clinical Infectious Diseases* | Oxford Academic. *Clin Infect Dis*.
4. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, Across HLH, Collaboration S. 2020. Correspondence COVID-19: consider cytokine storm syndromes and. *Lancet* 6736:19–20.
5. Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, Deng G. 2020. Association of inflammatory markers with the severity of COVID-19: a meta-analysis. *Int J Infect Dis* 96.
6. June CH, Sadelain M. 2018. Chimeric Antigen Receptor Therapy. *N Engl J Med* 379:64–73.
7. Grom AA, Horne A, De Benedetti F. 2016. Macrophage activation syndrome in the era of biologic therapy. *Nat Rev Rheumatol*. Nature Publishing Group.
8. Channappanavar R, Perlman S. 2017. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol*. Springer Verlag.
9. Gralinski LE, Bankhead A, Jeng S, Menachery VD, Proll S, Belisle SE, Matzke M, Webb-Robertson BJM, Luna ML, Shukla AK, Ferris MT, Bolles M, Chang J, Aicher L, Waters KM, Smith RD, Metz TO, Law GL, Katze MG, McWeeney S, Baric RS. 2013. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. *MBio* 4.
10. Velazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez LL, Borca M V. 2019. The Role of Interleukin 6 During Viral Infections. *Front Microbiol* 10:1057.
11. Percopo CM, Ma M, Brenner TA, Krumholz JO, Break TJ, Laky K, Rosenberg HF. 2019. Critical Adverse Impact of IL-6 in Acute Pneumovirus Infection. *J Immunol* 202:871–882.
12. Russell CD, Millar JE, Baillie JK. 2020. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. Lancet Publishing Group.

13. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Phil D, Sta-Plin N, Brightling C, Med F, Sci A, Ustianowski E, Elmahi M, Phil B, Prudon FRCP, Green C, Fel-Ton T, Chadwick D, Rege K-C, Path FRC, Fe-Gan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Mont-Gomery A, Rowan K, Juszczak E, Kenneth Bail-Lie J, Haynes R, Landray MJ. 2020. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. *N Engl J Med* NEJMoa2021436.
14. Gardner RA, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A, Gust J, Leger KJ, Tarlock K, Cooper TM, Finney OC, Brakke H, Li DH, Park JR, Jensen MC. 2019. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. *Blood* 134:2149–2158.
15. Frigault MJ, Nikiforow S, Mansour M, Hu Z-H, Horowitz MM, Riches M, Hematti P, Turtle CJ, Zhang M-J, Perales M-A, Pasquini MC. 2020. Tocilizumab not associated with increased infection risk after CAR T - Implications for COVID-19? *Blood* <https://doi.org/10.1182/blood.2020006216>.
16. Navarro G, Taroumian S, Barroso N, Duan L, Furst D. 2014. Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums. *Semin Arthritis Rheum* 43:458–469.
17. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, Cron RQ, Opal SM. 2016. Interleukin-1 Receptor Blockade Is Associated with Reduced Mortality in Sepsis Patients with Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*. *Crit Care Med* 44:275–281.
18. Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H. 2020. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. *Proc Natl Acad Sci U S A* 117:1–12.
19. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, Cossi S. 2020. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. *Eur J Intern Med* <https://doi.org/10.1016/j.ejim.2020.05.009>.
20. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, Franceschini F, Focà E, Andreoli L, Latronico N, Brescia International Research and Training HUB (BIRTH). 2020. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. *Autoimmun Rev* 102568.
21. Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, Bonora S, Calcagno A, Cecchi I, Cinnirella

- G, Converso M, Cozzi M, Crosasso P, De Iaco F, Di Perri G, Eandi M, Fenoglio R, Giusti M, Imperiale D, Imperiale G, Livigni S, Manno E, Massara C, Milone V, Natale G, Navarra M, Oddone V, Osella S, Piccioni P, Radin M, Roccatello D, Rossi D. 2020. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. *Clin Exp Rheumatol*.
22. Klopfenstein T, Zayet S, Lohse A, Balblanc J-C, Badie J, Royer P-Y, Toko L, Mezher C, Kadiane-Oussou NJ, Bossert M, Bozgan A-M, Charpentier A, Roux M-F, Contreras R, Mazurier I, Dussert P, Gendrin V, Conrozier T. 2020. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. *Med Mal Infect* <https://doi.org/10.1016/j.medmal.2020.05.001>.
23. Quartuccio L, Sonaglia A, McGonagle D, Fabris M, Peghin M, Pecori D, Monte A De, Bove T, Curcio F, Bassi F, Vita S De, Tascini C. 2020. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care. *J Clin Virol* 104444.
24. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, Zhou N, Petty LA, Baang JH, Dillman NO, Frame D, Gregg KS, Kaul DR, Nagel J, Patel TS, Zhou S, Luring AS, Hanauer DA, Martin E, Sharma P, Fung CM, Pogue JM. 2020. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. *Clin Infect Dis In Press*.
25. Gremese E, Cingolani A, Bosello SL, Alivernini S, Toluoso B, Perniola S, Landi F, Pompili M, Murri R, Santoliquido A, Garcovich M, Sali M, De Pascale G, Gabrielli M, Biscetti F, Montalto M, Tosoni A, Gambassi G, Rapaccini GL, Iaconelli A, Zileri Dal Verme L, Petricca L, Fedele AL, Lizzio MM, Tamburrini E, Natalello G, Gigante L, Bruno D, Verardi L, Taddeo M, Calabrese A, Lombardi F, Bernabei R, Cauda R, Franceschi F, Landolfi R, Richeldi L, Sanguinetti M, Fantoni M, Antonelli M, Gasbarrini A. 2020. Sarilumab use in severe SARS-CoV-2 pneumonia. *medRxiv* 2020.05.14.20094144.
26. Sanofi. 2020. Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients. Press Release.
27. Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, Justet A. 2020. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. *Ann Rheum Dis* <https://doi.org/10.1136/annrheumdis-2020-217706>.
28. Pontali E, Volpi S, Antonucci G, Castellaneta M, Buzzi D, Tricerri F, Angelelli A, Caorsi R, Feasi M,

- Calautti F, Castagnola E, Rollandi GA, Ravelli A, Cassola G, Gattorno M. 2020. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. *J Allergy Clin Immunol*
<https://doi.org/10.1016/j.jaci.2020.05.002>.
29. Yang ML, Wang CT, Yang SJ, Leu CH, Chen SH, Wu CL, Shiau AL. 2017. IL-6 ameliorates acute lung injury in influenza virus infection. *Sci Rep* 7.
30. WHO. 2020. WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis R&D Blueprint.
31. Robins JM, Hernán MÁ, Brumback B. 2000. Marginal structural models and causal inference in epidemiology. *Epidemiology* 11:550–560.
32. McCaw ZR, Tian L, Vassy JL, Ritchie CS, Lee C-C, Kim DH, Wei L-J. 2020. How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19. *Ann Intern Med*
<https://doi.org/10.7326/M20-4044>.
33. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh M, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC. 2020. Remdesivir for the Treatment of Covid-19 — Preliminary Report. *N Engl J Med*
<https://doi.org/10.1056/nejmoa2007764>.
34. Herold T, Jurinovic V, Arnreich C, Hellmuth JC, Bergwelt-Baildon M, Klein M, Weinberger T. 2020. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. *medRxiv* 2020.04.01.20047381.
35. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ, Group RC. 2020. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. *medRxiv* 2020.06.22.20137273.
36. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, Bouman CCS, Beenen

- LFM, Kootte RS, Heijmans J, Smits LP, Bonta PI, van Es N. 2020. Incidence of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost* <https://doi.org/10.1111/jth.14888>.
37. Sourì M, Mokuda S, Inanami H, Osaki T, Takasugi K, Ichinose A. 2016. Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab), p. 100–105. *In Thrombosis Research*. Elsevier Ltd.
38. Mokuda S, Murata Y, Sawada N, Matoba K, Yamada A, Onishi M, Okuda Y, Jouyama K, Sugiyama E, Takasugi K. 2013. Tocilizumab Induced Acquired Factor XIII Deficiency in Patients with Rheumatoid Arthritis. *PLoS One* 8.
39. McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Coddìng CE, Carlson TH, Delles C, Lee JS, Sattar N. 2015. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. *Ann Rheum Dis* 74:694–702.
40. Gualtierotti R, Ingegnoli F, Griffini S, Grovetti E, Meroni PL, Cugno M. 2016. Prothrombotic biomarkers in patients with rheumatoid arthritis: The beneficial effect of IL-6 receptor blockade. *Clin Exp Rheumatol* 34:451–458.
41. Wichmann D, Sperhake J-P, Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schröder AS, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S, Becker H, Brederke-Wiedling H, de Weerth A, Paschen H-R, Sheikhzadeh-Eggers S, Stang A, Schmiedel S, Bokemeyer C, Addo MM, Aepfelbacher M, Püschel K, Kluge S. 2020. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. *Ann Intern Med* <https://doi.org/10.7326/m20-2003>.
42. Hay KA, Hanafi L-A, Li D, Gust J, Liles WC, Wurfel MM, López JA, Chen J, Chung D, Harju-Baker S, Cherian S, Chen X, Riddell SR, Maloney DG, Turtle CJ. 2017. Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor-modified T Cell Therapy. *Blood* [blood-2017-06-793141](https://doi.org/10.1182/blood-2017-06-793141).
43. Kewan T, Covut F, Al MJ, Jaghbeer À, Rose L, Gopalakrishna K V, Akbik B. 2020. Tocilizumab for treatment of patients with severe COVID À 19: A retrospective cohort study. *EClinicalMedicine* 000:100418.

44. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, Franceschini E, Cuomo G, Orlando G, Borghi V, Santoro A, Di Gaetano M, Puzzolante C, Carli F, Bedini A, Corradi L, Fantini R, Castaniere I, Tabbì L, Girardis M, Tedeschi S, Giannella M, Bartoletti M, Pascale R, Dolci G, Brugioni L, Pietrangelo A, Cossarizza A, Pea F, Clini E, Salvarani C, Massari M, Viale PL, Mussini C. 2020. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. *Lancet Rheumatol* 0.
45. Rojas-Marte G, Khalid M, Mukhtar O, Hashmi AT, Waheed MA, Ehrlich S, Aslam A, Siddiqui S, Agarwal C, Malyshev Y, Henriquez-Felipe C, Sharma D, Sharma S, Chukwuka N, Rodriguez DC, Alliu S, Le J, Shani J. 2020. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study. *QJM An Int J Med* <https://doi.org/10.1093/qjmed/hcaa206>.
46. Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, Tomelleri A, Baldissera E, Rovere-Querini P, Ruggeri A, Monti G, De Cobelli F, Zangrillo A, Tresoldi M, Castagna A, Dagna L. 2020. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. *Eur J Intern Med* 76:43–49.
47. Colaneri M, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V, Brandolino F, Montecucco C, Mojoli F, Giusti EM, Bruno R, The Covid Irccs San Matteo Pavia Task Force. 2020. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). *Microorganisms* 8.
48. Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen S-C, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. 2020. Tocilizumab treatment for Cytokine Release Syndrome in hospitalized COVID-19 patients: survival and clinical outcomes. *Chest* <https://doi.org/10.1016/j.chest.2020.06.006>.
49. Potere N, Di Nisio M, Cibelli D, Scurti R, Frattari A, Porreca E, Abbate A, Parruti G. 2020. Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study. *Ann Rheum Dis* [annrheumdis-2020-218243](https://doi.org/10.1136/annrheumdis-2020-218243).

Table 1. Baseline demographics and clinical characteristics

	No tocilizumab (N=45)	Tocilizumab (N=43)	Total (N=88)	P ^a
Age				<.001
<50 yr	2 (4)	16 (37)	18 (20)	
50-70 yr	17 (38)	20 (47)	37 (42)	
≥70 yr	26 (58)	7 (16)	33 (38)	
Male sex	31 (69)	30 (70)	61 (69)	0.93
Race and ethnicity				<.001
Non-Hispanic white	30 (67)	8 (19)	38 (43)	
Non-Hispanic black	3 (7)	4 (9)	7 (8)	
Hispanic white	7 (16)	18 (42)	25 (28)	
Other	5 (11)	11 (26)	16 (18)	
Unknown	0 (0)	2 (5)	2 (2)	
Body-mass index				0.14
<29.9	23 (51)	17 (40)	40 (45)	
30-39.9	14 (31)	22 (51)	36 (41)	
≥40.0	8 (18)	4 (9)	12 (14)	
Past diagnoses^b				
Any diagnosis	40 (89)	31 (72)	71 (81)	0.05
Chronic lung disease	18 (40)	3 (7)	21 (24)	<.001
Diabetes	16 (36)	22 (51)	38 (43)	0.14
Cardiovascular disease	32 (71)	26 (60)	58 (66)	0.29
Chronic kidney disease	13 (29)	7 (16)	20 (23)	0.16
Immunocompromised	10 (22)	4 (9)	14 (16)	0.10
Autoimmune disease	1 (2)	1 (2)	2 (2)	1
Code status 'do not intubate'	17 (38)	5 (12)	22 (25)	0.005
Hospital location				0.05
1	11 (24)	20 (47)	31 (35)	
2	12 (27)	5 (12)	17 (19)	
3	22 (49)	18 (42)	40 (45)	
COVID-19 specific therapies^c				
Hydroxychloroquine, open label	25 (56)	35 (81)	60 (68)	0.009
Hydroxychloroquine or placebo, blinded trial	0 (0)	1 (2)	1 (1)	0.008
Remdesivir or placebo, blinded trial	15 (33)	11 (26)	26 (30)	0.57
Remdesivir, open label	0 (0)	1 (2)	1 (1)	1.0
Oxygen support category				<.001 ^d
Low-flow oxygen therapy	26 (58)	5 (12)	31 (35)	
Non-invasive ventilation or high-flow oxygen therapy	10 (22)	20 (47)	30 (34)	
Invasive ventilation	9 (20)	18 (42)	27 (31)	

Data are presented as No. (%), unless otherwise indicated.

^aChi-square/Fisher's exact test for categorical variables, as appropriate.

^bEach category was considered independently for % and p-value calculations. Chronic lung disease

included chronic obstructive pulmonary disease, asthma, and obstructive sleep apnea. Cardiovascular disease included hypertension, cardiovascular or cerebrovascular disease, and heart failure.

Immunocompromised included diagnoses of cancer, human immunodeficiency virus (HIV), solid organ transplant, and bone marrow transplant.

[°]Each category was considered independently for % and p-value calculations. At any time during the index hospitalization.

[°]Across all 3 oxygen support categories.

Table 2. Multivariable Cox models of time to clinical improvement or death within 28 days using IPTW weights (truncated to account for outliers) to weight the distribution of covariates to that of the overall population

Variable	Adjusted hazard ratio ^a	P-value	95% confidence interval
Clinical improvement			
Tocilizumab			
No	1.00		
Yes	0.92	0.85	0.38-2.22
Age group			
<50 yr	1.00		
50-70 yr	1.81	0.18	0.76-4.27
≥70 yr	1.35	0.67	0.33-5.44
Sex			
Male	1.00		
Female	0.95	0.92	0.37-2.44
Race and ethnicity			
Not non-Hispanic White	1.00		
Non-Hispanic White	0.58	0.29	0.21-1.59
Cardiovascular disease			
No	1.00		
Yes	0.46	0.08	0.19-1.11
Hospital			
1 or 2	1.00		
3	3.35	0.002	1.57-7.15
Code status 'do not intubate'			
No	1.00		
Yes	0.11	<0.001	0.04-0.29
Oxygen support category			
Low-flow oxygen therapy	1.00		
Non-invasive ventilation or high-flow oxygen therapy	0.51	0.25	0.16-1.59
Invasive ventilation	0.15	0.002	0.05-0.49
Mortality			
Tocilizumab			
No	1.00		
Yes	0.57	0.26	0.21-1.52
Age group			
<70 yr	1.00		
≥70 yr	3.99	0.006	1.48-10.77
Race and ethnicity			
Not non-Hispanic White	1.00		
Non-Hispanic White	0.38	0.08	0.13-1.12

Hospital

1 or 3	1.00		
2	2.44	0.11	0.82-7.29

Code status 'do not intubate'

No	1.00		
Yes	10.61	0.003	2.18-51.71

Oxygen support category

Low-flow oxygen therapy	1.00		
Non-invasive ventilation or high-flow oxygen therapy	2.65	0.09	0.87-8.0
Invasive ventilation	12.08	0.001	2.71-53.81

^aA hazard ratio (HR) <1 indicates a lower likelihood of clinical improvement or mortality, as relevant to the model.

Table 3. Potential complications associated with tocilizumab

	Tocilizumab cohort (N = 43)	No tocilizumab cohort (N = 45)
Bacteremia ^a	4 (9) ^b	2 (4) ^c
Ventilator-associated pneumonia ^d	9 (21) ^e	5 (11) ^f
AST or ALT >5x baseline ^g	4 (9)	2 (4)
Absolute neutrophil count <1,000 cells/mm ^{3h}	0 (0)	0 (0)
Platelet count <100,000 cells/mm ³ⁱ	5 (12)	2 (4)

Data are presented as number of individuals (%) and represent new events that occurred within 14 days of the baseline date.

^aDefined as positive blood cultures that were treated with antibiotics.

^bPathogens consisted of coagulase-negative Staphylococci (CONS), *Serratia marscecens*, and *Enterococcus faecalis*.

^cPathogens consisted of methicillin-sensitive *Staphylococcus aureus* (MSSA), *Granulicatella adiacen*, and CONS.

^dDefined as microbiologic documentation in addition to antimicrobial therapy. All events occurred in patients who were mechanically ventilated in both cohorts.

^ePathogens consisted of MSSA, *Haemophilus influenzae*, *Escherichia coli*, *Serratia marscecens*, methicillin-resistant *Staphylococcus aureus* (MRSA), *Klebsiella pneumoniae*, and *Klebsiella variicola*.

^fPathogens consisted of *Haemophilus influenzae*, *Sterptococcus pneumoniae*, MSSA, *Enterobacter aerogenes*, and *Serratia marcescens*.

^g7 patients did not have any results, and 11 patients did not have any results after baseline.

^h1 patient did not have any results, and 7 patients did not have any results after baseline.

ⁱ5 patients had an absolute neutrophil count <1,000 cells/mm³ at baseline; 3 patients did not have any results after baseline.

Table 4. Peer-reviewed retrospective studies with comparator groups of clinical outcomes in patients treated with tocilizumab for COVID-19

	Invasive ventilation	Toci dose	Antivirals used in majority	Steroid use	Clinical improvement	Mortality	Secondary infections	Other reported adverse effects
Guaraldi (44) Toci: N = 179 No Toci: N=365	Toci: 18% No Toci: 16%	8 mg/kg x 2 IV or 162 mg x 2 SC	HCQ, Azithro, and L/R or D/C	Toci: 30% No Toci: 17%	Toci: 23% died or mechanically ventilated No Toci: 37% died or mechanically ventilated by day 14	Toci: 7% No Toci: 20%	Toci: 13% No Toci: 4%	Severe neutropenia (n=1), injection site reaction (n=1)
Somers (24) Toci: N = 78 No Toci: N = 76	Toci: 100% No Toci: 100%	8 mg/kg x 1	None	Toci: 29% No Toci: 20%	Toci: 45% reduction in hazard for death	Toci: 18% No Toci: 36% (by day 28)	Toci: 54% No Toci: 26%	None reported
Rojas-Marte (45) Toci: N = 96 No Toci: N = 97	Toci: 64% No Toci: 62%	Not reported	HCQ, Azithro	Toci: 43% No Toci: 33%	Length of hospital stay: Toci 14.5 ± 8.8 days, No Toci: 16.5 ± 10.8 days	Toci: 45% No Toci: 57%	Toci: 13% bacteremia, 4% fungemia No Toci: 24% bacteremia, 3% fungemia	None reported
Capra (19) Toci: N = 62 No Toci: N = 23	0	400 mg x 1 IV or 324 mg SC	HCQ, L/R	No	Toci: 92% ^a No Toci: 42% ^a complete recovery	Toci: 8% ^a No Toci: 58% ^a	None	Not reported
Campochiario (46) Toci: N = 32 No Toci: N = 33	0	400 mg x 1, no second doses	HCQ, Azithro, L/R	No	Toci: 69% No Toci: 61% improvement by 28 days	Toci: 15% No Toci: 33% (by day 28)	Toci: 13% No Toci: 12%	Transient increase in AST/ALT (Toci: 15%, No Toci: 18%); transient neutropenia (Toci: 16%, No Toci: 0%)

Colaneri (47) Toci: N = 21 No Toci: N = 21	Not reported	8 mg/kg x 2	HCQ, Azithro	All subjects	No difference in risk for ICU admission or death by 7 days	Toci: 24% No Toci: 21% (by day 7)	None	None
Klopfenstein (22) Toci: N = 20 No Toci: N = 25	Not reported	Not reported	HCQ, L/R	Not reported	Toci: 25% died or admitted to ICU No Toci: 72% died or admitted to ICU	Toci: 25% No Toci: 48%	Not reported	Not reported
Quartuccio (23) Toci: N = 42 No Toci: N = 69	Toci: 62% No Toci: 0	8 mg/kg x 1	HCQ, L/R or D/C	Toci: 38% No Toci: 0	Toci: 71% No Toci: 100% clinical improvement	Toci: 10% No Toci: 0%	Toci: 43% No Toci: 0%	Not reported
Price (48) Toci: N = 153 No Toci: N = 86	Toci: 31% No Toci: 6%	8 mg/kg x 1, max 800 mg	HCQ	20% overall	Toci: 86% No Toci: 87% 14-day survival	Toci: 14% No Toci: 13% by day 14	Toci: 3% (bacteremia)	Toci: 4% neutropenia
Kewan (43) Toci: N = 28 No Toci: N = 23	Toci: 75% No Toci: 48%	400 mg x 1	HCQ, Azithro	Toci: 71% No Toci: 48%	Shorter time to clinical improvement	Toci: 14% No Toci: 18%	Toci: 18% No Toci: 22%	None
Potere (49) Toci: N = 40 No Toci: N = 40	Toci: 0% No Toci: 0%	324 mg x 2 SC	HCQ	Toci: 65% No Toci: 58%	Toci: 93% No Toci: 73% improvement on ordinal scale by day 35	Toci: 5% No Toci: 28% by day 35	Toci: 3% No Toci: 8%	Toci: ALT rise (3%)

N indicates number; HCQ, hydroxychloroquine; L/R, lopinavir/ritonavir; D/C, darunavir/cobicistat; azithro, azithromycin; IFN, interferon; toci, tocilizumab; SC, subcutaneous.

^aAmong those who met an endpoint of discharge from the hospital or death, which was met by 25 of patients in the tocilizumab group and 19 in the control group.

It is important to note that tocilizumab dose and administration timing, as well as definitions of clinical improvement, secondary infections, and adverse events varied by study.

Figure 1. The proportion of patients in each baseline severity category who had clinical improvement by 28 days among patients in the tocilizumab and no tocilizumab groups

White boxes indicate clinical improvement for the indicated baseline severity category, light gray indicate neither improvement nor worsening, and dark grey indicate worsening. Percentages are column percentages based on the baseline severity category.

Figure 2. Cumulative incidence of sustained (≥ 3 days) clinical improvement within 28 days among patients who did and did not receive tocilizumab using the inverse probability of treatment (IPT) weighted population

Death was treated as a competing risk event.

Figure 3. Kinetics of inflammatory laboratory markers

IL-6 indicates interleukin 6 (pg/mL); CRP, C-reactive protein (mg/L); LDH, lactate dehydrogenase (U/L). Units for other laboratory values are ng/mL for ferritin, mcg/mL for D-dimer, mg/dL for fibrinogen.

The presented data indicate medians and the associated interquartile ranges. If multiple values were available for the same day, the maximum value was used. The number of patients contributing results to each panel are in **Table S6**. In Panel A, the late secondary increase in IL-6 levels was driven by 2 individuals who had progressive cardiopulmonary disease with concurrent bloodstream infections and ventilator-associated pneumonias at the time of secondary IL-6 increase.

A. Tocilizumab cohort

B. No tocilizumab cohort






Figure 1. The proportion of patients in each baseline severity category who had clinical improvement by 28 days among patients in the tocilizumab and no tocilizumab groups


A. Overall



B. Low-flow oxygenation subgroup



C. High-flow oxygenation subgroup



D. Invasive ventilation subgroup




Figure 2. Cumulative incidence of sustained (≥3 days) clinical improvement within 28 days among patients who did and did not receive tocilizumab using the inverse probability of treatment (IPT) weighted population




Figure 3. Kinetics of inflammatory laboratory markers